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Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized
by the accumulation and aggregation of extracellular amyloid β (Aβ) peptides and
intracellular aggregation of hyper-phosphorylated tau protein. Recent evidence indicates
that accumulation and aggregation of intracellular amyloid β peptides may also play
a role in disease pathogenesis. This would suggest that intracellular Heat Shock
Proteins (HSP) that maintain cellular protein homeostasis might be candidates for
disease amelioration. We recently found that DNAJB6, a member of DNAJ family
of heat shock proteins, effectively prevented the aggregation of short aggregation-
prone peptides containing large poly glutamines (associated with CAG repeat diseases)
both in vitro and in cells. Moreover, recent in vitro data showed that DNAJB6
can delay the aggregation of Aβ42 peptides. In this study, we investigated the
ability of DNAJB6 to prevent the aggregation of extracellular and intracellular Aβ
peptides using transfection of human embryonic kidney 293 (HEK293) cells with
Aβ-green fluorescent protein (GFP) fusion construct and performing western blotting
and immunofluorescence techniques. We found that DNAJB6 indeed suppresses Aβ-
GFP aggregation, but not seeded aggregation initiated by extracellular Aβ peptides.
Unexpectedly and unlike what we found for peptide-mediated aggregation, DNAJB6
required interaction with HSP70 to prevent the aggregation of the Aβ-GFP fusion
protein and its J-domain was crucial for its anti-aggregation effect. In addition, other
DNAJ proteins as well as HSPA1a overexpression also suppressed Aβ-GFP aggregation
efficiently. Our findings suggest that Aβ aggregation differs from poly glutamine (Poly
Q) peptide induced aggregation in terms of chaperone handling and sheds doubt
on the usage of Aβ-GFP fusion construct for studying Aβ peptide aggregation in
cells.
Keywords: Aβ-GFP, heat shock proteins, amyloid beta aggregation, Alzheimer’s disease, chaperones, DNAJB6
Abbreviations: Aβ, Amyloid β; AD, Alzheimer disease; APP, amyloid precursor protein; GFP, Green fluorescent
protein; HSP, Heat shock protein; HEK293, Human embryonic kidney 293; Poly Q, Poly glutamines; Wt, Wild type.
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Introduction
Alzheimer’s disease (AD) is the most prevalent cause of
dementia in the elderly. It is estimated that more than
35 million people are affected with AD worldwide and
this number is expected to grow exponentially in the next
years (Reitz et al., 2011; Huang and Mucke, 2012). The
key pathological changes associated with AD brains are
the deposition of extracellular amyloid plaques composed of
amyloid beta (Aβ) peptides and deposition of intracellular
neurofibrillary tangles composed of hyperphosphorylated tau
protein and reactive microgliosis (Takata and Kitamura,
2012).
Aβ is produced in the brain after the cleavage of the
transmembrane amyloid precursor protein (APP) by two
sequential proteases. Initially, APP is cleaved by the β-secretase
that releases the sAPPβ ectodomain and a C-terminal fragment
named C99, which is subsequently cleaved by the complex γ-
secretase enzyme into the APP intracellular domain (AICD) and
Aβ peptides with different amino acid lengths (37–43 amino
acids) of which the Aβ42 species are considered as more toxic
(Shankar et al., 2009) and aggregation prone peptides (O’Brien
and Wong, 2011; Zheng and Koo, 2011; Haass et al., 2012;
Bignante et al., 2013). Interestingly, C99 fragments generated
after the cleavage of APP by β secretase were found to play an
early and crucial role in AD pathogenesis in addition to their role
as substrates for the production of both Aβ and AICD (Lauritzen
et al., 2012).
Aβ peptides are able to self-aggregate into numerous
assemblies ranging from Aβ dimers, soluble oligomers, proto-
fibrils and amyloid plaques, which are believed to exist in
equilibrium and to have different toxic propensities (Shankar
et al., 2009; Benilova et al., 2012). In the classical amyloid
cascade hypothesis, it has been suggested that the accumulation
of the Aβ peptides into the extracellular plaques is the central
cause of AD (Hardy and Higgins, 1992; Selkoe, 2006). However,
recent data also suggest a crucial role for the intracellular Aβ in
the pathogenesis of this disease (Armogida et al., 2001; Wirths
et al., 2004; LaFerla et al., 2007; Gouras et al., 2010). APP
together with its proteolytic enzymes β and γ secretases are
not only localized on the plasma membrane, but also on other
intracellular membranes such as the Golgi network, endosomes
and on mitochondrial membranes via which Aβ peptides are
produced intracellularly. These additional intracellular sites
for Aβ production may be limited to neurons (Xu et al.,
1995; Pasternak et al., 2003; Yu et al., 2005). Interestingly,
accumulation of intracellular Aβ was detected before the
appearance of amyloid plaques in transgenic AD mice where it
was associated with the onset of cognitive impairment (Billings
et al., 2005; Knobloch et al., 2007). Also in patients with AD and
Down’s syndrome, intracellular Aβ was detected in post-mortem
brains (Cataldo et al., 2004). Furthermore, this intracellularly
generated Aβ found to be more potent in causing neuronal cell
death than extracellular Aβ (Kienlen-Campard et al., 2002). Some
findings even suggest that Aβ plaques are a late consequence
of the intracellular Aβ peptide generation and export (Gyure
et al., 2001; Gouras et al., 2005) meaning that intracellular Aβ
somehow initiate extracellular plaques formation (Cataldo et al.,
1994; D’Andrea and Nagele, 2010).
If intracellular Aβ and its aggregation indeed are important
in AD initiation, it would be worthwhile to test if and how
(components of) the intracellular protein quality control system
might be able to handle Aβ peptides. Recent data have suggested
that especially DNAJB6, an ubiquitously expressed member
of DNAJ family of heat shock proteins (HSPs), might be an
extremely efficient suppressor of aggregation initiated by small
peptides. In fact, DNAJB6 was shown to efficiently prevent
the aggregation of poly glutamines (Poly Q) peptides in vitro
(Månsson et al., 2014b) and in cells (Gillis et al., 2013). As such,
it was found to be a very efficient suppressor of poly Q protein
aggregation and toxicity in cells, in a Xenopus model of poly Q
aggregation (Hageman et al., 2010) and in a Drosophila model
of Huntington’s disease (Fayazi et al., 2006). Importantly, we
recently found that DNAJB6 is very effective in preventing the
fibrillation of Aβ42 peptides in vitro, where it inhibits the primary
and secondary nucleation pathways of Aβ through binding to
different Aβ aggregated species (Månsson et al., 2014a). Like
all members of the DNAJ family, DNAJB6 has an N-terminal
J-domain which contains a conserved histidine, proline, and
aspartic acid residues (HPD motif) that is essential for the
interaction with HSP70 and stimulation of its ATPase activity.
These results prompted us to investigate the effect of DNAJB6
overexpression on the aggregation induced by intracellular
(using an Aβ-green fluorescent protein, GFP fusion protein) as
well as extracellular Aβ peptides. We found that DNAJB6 indeed
prevented the intracellular aggregation of Aβ-GFP. However,
based on DNAJB6 mutant analyses and on the comparison
with other HSP members, our results shed doubt on whether
aggregation of Aβ-GFP fusion actually is an appropriate model
for studying intracellular Aβ peptide aggregation.
Materials and Methods
Plasmid Construction
The ubiquitin-fusion protein used in this study; Ub-Aβ42-
GFP was a kind gift from Dr. Eric Reits (Department of Cell
Biology and Histology, Academic Medical center, Amsterdam,
Netherlands). Aβ peptides-ATTO 550 fibrils were a kind gift
from Dr. Ronald Melki (Laboratoire d’Enymologie et Biochimie
Structurales, Center National de la Recherche Scientifique,
France). The chaperones constructs: pcDNA5/FRT/TO
V5 DNAJB6b, pcDNA5/FRT/TO V5 DNAJB6b(H31Q),
pcDNA5/FRT/TO V5 DNAJA1, pcDNA5/FRT/TO V5 DNAJB1
and pcDNA5/FRT/TO V5 HSPA1a were described before in
Hageman et al. (2010). HSPBs constructs; FRT-TO-HSPB1,
FRT-TO-HSPB5 and FRT-TO-HSPB7 were described in Vos
et al. (2009).
Purification of the Recombinant Aβ42 Peptides
The DNA encoding Aβ42 peptide was amplified using the
primers 5′-CCCGGGAATTCCATATGGACGCGGAATTT
CGCCATGATAGCGGC-3′ and 5′-TCCGCGGGATCCCTA
CTATGCAATCACGACGCCTCCGACC-3′ that introduced an
N-terminal Met codon. The amplified DNA was cloned into
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the pET3a vector (Novagen, Darmstadt, Germany) between
the NdeI and BamH1 restriction sites and expressed in E.
coli strain BL21(DE3) codon+ (Stratagene). Recombinant
Aβ1-42 was purified as described in Walsh et al. (2009). For
fibrillation, Met-Aβ1-42 was diluted in phosphate-buffered
saline (PBS) to a concentration of 100 µM and incubated
at 37◦C for 5 days. Met-Aβ1-42 fibrils in PBS were labeled
by addition of two molar excess of NHS-ester ATTO-550
(ATTO-TEC, Siegen, Germany). Labelling was performed
following the manufacturer’s recommendations giving rise
to Aβ42-ATTO 550. Unreacted dye was removed by three
cycles of sedimentation at 50,000 g and suspension of the
fibrils in PBS.
Cell Culture and Transfections
Human embryonic kidney cells stably expressing the tetracycline
repressor, Flp–In T-REx human embryonic kidney 293 cells
(HEK 293; Invitrogen, Carlsbad, CA, USA, Catalog number:
R780-07) were grown in Dulbecco’s Modified Eagle Medium
(DMEM, GIBCO). The medium was supplemented with 10%
fetal calf serum (Greiner Bio-one, Long wood, FL, USA) plus 100
units/ml penicillin and 100 mg/ml streptomycin (Invitrogen).
The cells were grown at 37◦C under a humidified atmosphere
containing 5% CO2. Blasticidin (5 µg/ml, GIBCO, Invitrogen)
was regularly added in the culture medium of the cells and
tetracycline (1 µg/ml, Sigma) was added to switch on the
expression of pcDNA5/ FRT/TO chaperones when needed.
HEK293 cells were plated at density 2 × 105 cells/9.6 cm2
on 0.001% poly-L-lysine (Sigma) coated wells for 24 h before
transfections. Usually 0.5–1 µg of Ub-Aβ42-GFP with or without
different chaperones at 1:3 ratio were transfected into HEK293
cells by polyethylenimine (PEI) transfection reagent (1 µg/µl,
Polysciences) for 48 h before cell lysis.
Cell Fractionation and Western Blotting
Cells were washed twice with ice-cold PBS and lysed into 2×
Tris lysis buffer (100 mM Tris-HCl pH 7.5, 300 mM NaCl,
10 mM EDTA pH 8.0, 1% Triton X100) supplemented with
Protease inhibitor cocktail (Roche Diagnostics, Germany). Cell
lysates were incubated in ice for 30 min and centrifuged at
14,000 rpm at 4◦C for 20 min. The supernatants were collected
and used as soluble fractions while the pellet fractions were
washed once with PBS and then dissolved into sodium dodecyl
sulfate (SDS) in PBS buffer. Samples were mixed with 2×
Laemmli sample buffer with 5% β-mercaptoethanol (Sigma)
and boiled for 5 min. Samples were separated either on 12.5%
glycine SDS-polyacrylamide gel electrophoresis (PAGE) to detect
Aβ42-GFP, HSPs and β-actin or separated onto 12% Tricine-
SDS PAGE to detect Aβ peptides according to Schägger (2006).
After gel electrophoresis, the separated proteins were transferred
into nitrocellulose membranes. The membranes were blocked
with 5% dry milk in PBS with 0.1% Tween 20 (PBST) for
1 h at room temperature and incubated overnight at 4◦C
with the following primary antibodies: 6E10 (1:1000 in TBST,
Covance), anti V5 (1:5000 in PBST, Invitrogen), anti β-actin
(1:1000 in PBST, Abcam), anti HSPB1 (1:1000 in PBST, Stress
Marq Biosciences), anti HSPB5 (1:1000 in PBST, Stress Marq
Biosciences) and anti HSPB7 (1:1000, Abnova). The next day,
the membranes were washed with PBST and incubated with
anti mouse HRP-conjugated secondary antibody (1:5000 in
PBST, GE Healthcare) for 1 h at room temperature. Enhanced
chemiluminescence (ECL) was used for protein detection using
ECL western blotting substrate kit (Thermoscientifc). Bands
were visualized by exposure of the membranes to Amersham
Hyperfilm ECL (GE Heath Care, UK).
Immunofluorescence Microscopy
One day before transfection, HEK293 cells were plated onto
0.001% poly L-lysine coated cover slips. Cells were transiently
transfected with 0.5 µg Ub-Aβ42-GFP and either 1.5 µg of
DNAJB6b-V5 or FRTTO for 48 h. In case of testing extracellular
Aβ42 peptides, 1µMof Aβ42-ATTO 550 fibrils were exogenously
added after 24 h transfection into the culture medium of the
cells for another 24 h. Cells were washed three times with
PBS, fixed with 3.7% formaldehyde in PBS for 15 min and
permeabilized with 0.2% Triton X-100 in PBS for another 15min.
Cells were blocked with 100 mM glycine for 10 min then with
3% bovine serum albumin (BSA) in PBST for 30 min. Cells were
incubated with primary antibody: rabbit anti V5 (1:200 in PBS-
T, Life Technology) overnight at 4◦C. Coverslips were washed
with PBS-T and incubated with anti rabbit Alexa Fluor 594
(1:250 in PBST, Life Technology) for 1 h at room temperature.
Coverslips were washed with PBS-T and incubated with 0.2
µg/ml 4, 6-diamidino-2-phenylindole (DAPI) for 10 min to stain
the nuclei. Coverslips were washed with PBS and mounted with
Citifluor medium (Citifluor Ltd., London, UK). Extracellular
Aβ42 peptides were detected by tracking the fluorescent tag,
ATTO 550. Images were obtained with Leica TCS SP8 confocal
laser scanning microscope with HC PL APO CS2 63×/1.4 oil
objective.
Data Analysis
Data are expressed as mean ± SE of at least two independent
experiments. Densitometry of western blot bands was calculated
using Image Studio Lite software, LI-COR Biosciences,
USA. Student’s t test was used for calculation of the
statistical significance where ∗P < 0.05, ∗∗P < 0.01 and
∗∗∗P < 0.001.
Results
Generation of Intracellular Amyloid Beta (Aβ)
In order to study the effect of the molecular chaperone
DNAJB6 on intracellular Aβ aggregation, we initially transfected
HEK293 cells with GFP-Ub-Aβ42 construct. Upon expression,
this construct is cleaved by the endogenous deubiquitinating
enzymes into GFP-Ub and free Aβ42 peptides. Unfortunately,
we were unable to detect intracellular free Aβ42 peptides.
Apparently, the Aβ42 peptides are rapidly degraded. But, more
relevant to this study, we transfected HEK293 cells with an
Ub-Aβ42-GFP construct that generates Aβ42-GFP fusion peptide
(Figure 1A). We found that a substantial fraction of the Aβ42-
GFP fusion peptides ends up in the Triton X-100 insoluble
(P) fraction of the transfected cells (Figure 1B). Consistently,
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FIGURE 1 | DNAJB6 prevents the aggregation of Aβ42-GFP. (A) Scheme
of generation of Aβ42-GFP intracellularly. Cells were transfected with
Ub-Aβ42-GFP. Upon expression, Ub-Aβ42-GFP is cleaved by endogenous
ubiqutin C-terminal hydrolases after the RGG amino acid sequence to give rise
to Ub and Aβ42-GFP at 1:1 ratio. (B) HEK293 cells were transfected with 0.5
µg Ub-Aβ42-GFP with FRTTO-DNAJB6b-V5 at 1:1, 1:2 ratio or FRTTO as a
control (1:0 ratio). After 48 h, cells were lysed and separated into Triton X100
(Continued)
FIGURE 1 | Continued
soluble (S) and pellet (P) fractions (left panel) or total lysate (right panel). A
β42-GFP and DNAJB6-V5 were detected by Western blotting with 6E10 and
anti V5 antibodies respectively. β-actin was used as a loading control. The
quantification of pellet/Soluble ratio relative to FRTTO were depicted in the
chart above the blot. Values represent mean ± SE of three independent
experiments. (C) HEK293 cells were transfected with Ub-Aβ42-GFP and
either DNAJB6-V5 at 1:3 ratio or FRTTO as a control. Cells were fixed and
immunostained with α-V5 (red) antibody to detect DNAJB6-V5. α-GFP (green)
was used to detect Aβ-GFP and DAPI (blue) was used for DNA staining. The
panel shows confocal images of mock cells (upper panel), cells transfected
with Ub-Aβ-GFP with FRTTO (middle panel), cells transfected with Ub-Aβ-GFP
and DNAJB6 (lower panel). Scale bar = 5 µm. (D) HEK293 cell line, stably
expressing DNAJB6 was transfected with 0.2, 0.3 or 0.5 µg of Ub-Aβ42-GFP.
Tetracycline was added to switch on the expression of DNAJB6. Cell lysates
were fractionated into Soluble (S) and Pellet (P) and analyzed using western
blotting as in panel (B).
we found Aβ42-GFP to accumulate in Aβ42-positive puncta
both in the cytosol and inside the nuclei of the transfected
cells (Figure 1C), together suggesting that Aβ42-GFP is indeed
aggregated. Of note, no Aβ42-GFPwas detected as highmolecular
weight material (in the stacking gel) and we were unable to
detect Aβ42-GFP aggregates in filter trap assays, suggesting that
although it is aggregated, Aβ42-GFP did not form SDS-insoluble
(amyloid-like) structures.
DNAJB6 Prevents the Aggregation of Aβ42-GFP
To investigate whether DNAJB6 can inhibit aggregation
of the intracellularly generated Aβ42-GFP, we transfected
HEK293 cells with Ub-Aβ42-GFP and FRTTO-DNAJB6-
V5 at different ratios (1:1 and 1:2). We found that, in cells
expressing DNAJB6, the fraction of TritonX-100 insoluble
Aβ42-GFP decreases whilst its amount in the TX-100
soluble fraction increases (Figure 1B). In parallel, cells
expressing the V5-tagged-DNAJB6 contained less Aβ42-
GFP puncta and showed a more diffuse Aβ42-GFP signal
(Figure 1C).
We next confirmed these findings using a HEK293 cell
line stably expressing DNAJB6-V5 under the control of a
tetracycline-regulated promoter. Transfecting this cell line with
increasing concentrations of Ub-Aβ42-GFP plasmid lead to a
dose dependent increase in Aβ42-GFP insolubilization, which
was prevented when DNAJB6 expression was turned on
(Figure 1D).
DNAJB6 Depends on HPD Motif to Prevent
Aβ-GFP Aggregation
To explore if the J-domain of DNAJB6 is essential to prevent
the aggregation of Aβ-GFP or not, we transfected the HEK293
cells with Ub-Aβ42-GFP and with either DNAJB6 (wild type,
wt) or DNAJB6 with a point mutation (H31Q) in the conserved
HPD motif to inactivate the J-domain. Strikingly, we found
that the J-domain mutant (H31Q) was less effective than wt
protein in preventing the aggregation of Aβ-GFP suggesting
that DNAJB6 was clearly dependent on interaction with HSP70
(Figure 2A). It should also be noted that the efficiency of
DNAJB6 wt and mutant protein to prevent Aβ-GFP aggregation
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FIGURE 2 | DNAJB6 depends on HPD motif to prevent
Aβ42-GFP aggregation. (A) HEK293 cells were transfected with
Ub-Aβ42-GFP with either DNAJA1, DNAJB1, DNAJB6 (Wt), DNAJB6
(H31Q) mutants at 1:3 ratio for 48 h. Cells were lysed, fractionated
into T, S, P and Western blotting was performed (B) HEK293 cells
were transfected with Ub-Aβ42-GFP with either FRTTO (control) or
HSPA1a at 1:3 ratio for 48 h. Quantification of the pellet/soluble ratio
of Aβ-GFP relative to FRTTO was depicted in the charts above the
blots. Values represent mean ± SE of two independent experiments.
*P < 0.05, ***P < 0.001, ns = non significant.
was inversely related to steady state expression levels of the
Aβ-GFP fusion protein (T-fractions in Figure 2A) since it
was previously shown that J-domain is important for at least
DNAJB1 and DNAJB2a (Bailey et al., 2002; Westhoff et al., 2005)
and partly to DNAJB6 (Hageman et al., 2010) to prevent the
aggregation of poly Q repeats through a mechanism dependent
on HSP70 interaction followed by proteasomal degradation. This
may explain the observed increase in the total Aβ-GFP protein
when J-domain was mutated in DNAJB6 (H31Q). Additionally,
Månsson et al. (2014a) found that DNAJB6 is interacting with
the very early aggregates of Aβ peptides to prevent further
aggregation and failing to do so leads to incorporation of
DNAJB6 into the fibrils formation. This would explain the
considerable amounts of DNAJB6 (H31Q) localized in the pellet
fraction (Figure 2A).
Since the anti-aggregation activity of DNAJB6 showed a
dependence on the HPD motif, which is conserved in all
members of DNAJs, we also investigated whether or not
other canonical members of DNAJ family could prevent
the aggregation of Aβ-GFP. Overexpression of DNAJA1 and
DNAJB1 result in protection against Aβ-GFP aggregation
(Figure 2A). In accordance with this finding, overexpression
of HSPA1a (a canonical member of HSP70) lead to a
reduced aggregation of Aβ-GFP (Figure 2B). This indicates
that the inhibition of Aβ-GFP aggregation by DNAJB6 is
not unique but it is shared with other members of DNAJ
family.
Canonical Members of HSPB Family Prevent the
Aggregation of Aβ-GFP
Next, we tested a number of HSPB chaperones on Aβ-
GFP aggregation. We found that HSPB7 did not reduce the
insolubilization of Aβ-GFP and even enhanced it (Figure 3).
In contrast, HSPB1 was found to be effective in reducing
insolubilization of Aβ-GFP (Figure 3). Finally, HSPB5 which
could enhance the refolding of heat denatured firefly luciferase
(Vos et al., 2010), here it did not have an effect on Aβ-GFP
aggregation. Together, these findings further support our notion
that Aβ-GFP requires different chaperone handling than peptide
fragments.
DNAJB6 Neither Prevent the Uptake of Nor
Dissolve Exogenous Aβ42-ATTO Assemblies
After they have been Taken Up
It has been suggested that the extracellular Aβ peptides
re-enter the cells then trigger intracellular Aβ aggregation
through a templating mechanism, thus contributing to
neuronal toxicity (Nagele et al., 2002; Crews and Masliah,
2010). To test whether intracellular chaperone elevation
either affects extracellular Aβ42 peptides or their stability
within the cytosol after they have been taken up, cells
were exposed to 1 µM of extracellularly added Aβ42
fibrils tagged with the fluorescent dye ATTO 550 to
facilitate their tracking (Freundt et al., 2012). After 24 h,
the cells were fixed and analyzed by confocal microscopy.
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FIGURE 3 | Canonical members of HSPB family prevent the
aggregation of Aβ-GFP. Cells were transfected with HSPB1, HSPB5,
HSPB7 or FRTTO at 1:3 ratio for 48 h. Quantification of the pellet/soluble ratio
of Aβ-GFP relative to FRTTO was depicted in the chart above the blot. Values
represent mean ± SE of two independent experiments. ∗∗P < 0.01, ns = non
significant.
As demonstrated by others (Hu et al., 2009; Friedrich et al.,
2010), Aβ42 fibrils are internalized and form intracellular
foci (Figure 4A). DNAJB6 overexpression neither prevented
extracellularly added Aβ42 fibrils take-up and their subsequent
intracellular foci formation nor the solubility of fibrils
(Figure 4B). Indeed, western blot analyses showed that
extracellularly added Aβ42 fibrils remained insoluble upon
DNAJB6 overexpression (Figure 4E, compare lanes 7,
8 with lanes 11, 12).
Aβ42-GFP Aggregates do not Co-Localize with
Extracellular Aβ42-ATTO Peptides
Next, we tested whether the extracellularly added Aβ42 fibrils
could seed the assembly of intracellular Aβ42-GFP, an effect
that was clearly demonstrated for poly Q aggregates in a
similar study (Ren et al., 2009). Surprisingly, we found
that exogenous Aβ42 fibrils did not increase Aβ42-GFP
aggregation. Confocal analyses did not show any co-localization
between Aβ42-GFP and exogenous Aβ42-ATTO 550 fibrils
(Figure 4C) suggesting that exogenous Aβ42 peptides do not
template Aβ42-GFP aggregation. This is further confirmed
by the observation that the amount of Aβ-GFP aggregates
did not increase upon addition of exogenous Aβ fibrils
(Figure 4E compare lanes 1, 2 with lanes 9, 10). From these
observations, we suggest that the Aβ42-GFP fusion product
may not reflect the same characteristics of Aβ42 peptide
aggregation.
FIGURE 4 | Aβ42-GFP aggregates do not co-localize with extracellular
Aβ42-ATTO peptides. (A) One micromolar of Aβ42-ATTO 550 fibrils were
added into the culture medium of HEK293 cells for 24 h Cells were fixed and
stained with DAPI for nuclear staining. Confocal images were acquired by
Leica SP8 confocal microscope. Extracellular Aβ peptides can enter the cells
and form intracelluar aggreagtes. (B) HEK293 cells were transfected with
DNAJB6-V5 in 1:3 ratio. After 24 h transfection, 1 µM of Aβ42 fibrils were
added into the culture medium of cells for another 24 h and cells were fixed
and stained with anti V5. Confocal images show that DNAJB6 cannot prevent
the extracellular Aβ mediated aggregation. (C) Cells were transfected with 1µg
Ub-Aβ-GFP. After 24 h transfection, 1 µM of Aβ42 fibrils were added into the
culture medium of cells for another 24 h Cells were fixed. Confocal images
show that extracellular Aβ peptides do not co-localize with Aβ-GFP. (D) Cells
were transfected with Ub-Aβ-GFP and DNAJB6 in 1:3 ratio for 24 h then 1 µM
of Aβ42-ATTO 550 fibrils were added into the culture medium of HEK293 cells
for another 24 h Cells were fixed and immunostained as mentioned above
except that DNAJB6 is not stained for. Images show that DNAJB6 can still
decrease the aggregation of intracellular Aβ42-GFP in presence of
extracellular Aβ peptides. ATTO 550 was used to detect extracellular Aβ
peptides, GFP for Aβ42-GFP, anti V5 for DNAJB6 and DAPI for nuclei. DIC:
differential interference contrast. Scale bar = 5 µm. (E) Western blot of cells
transfected and fractionated as mentioned above.
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Interestingly, DNAJB6 was still able to prevent the
aggregation of the intracellular Aβ42-GFP in the presence
of exogenous Aβ peptides as revealed both by confocal imaging
(Figure 4D) and by cell fractionation (Figure 4E compare lanes
3, 4 with lanes 5, 6).
Discussion
In this study, we investigated the effect of the molecular
chaperones, in particular DNAJB6, on the aggregation of
Aβ associated with AD. We found that DNAJB6 effectively
prevented the aggregation of Aβ-GFP that are generated
intracellularly via a canonical dependence on J-domain.
Interestingly, DNAJB6 could not neither affect exogenous
Aβ fibrils take-up nor the stability of those peptides after
take-up.
We had special interest in DNAJB6 because it was previously
shown to strongly inhibit the aggregation of poly Q peptides
(Månsson et al., 2014b) and Aβ42 peptides (Månsson et al.,
2014a) in vitro. Since also intracellular pools of Aβ peptides were
suggested to be involved in disease pathogenesis (Oddo et al.,
2006; see also ‘‘Introduction’’ Section), we reasoned that DNAJB6
could be a potential repressor of intracellular Aβ42 aggregation
and thus potentially of target for AD.
However, DNAJB6 and other HSPs exhibited different effects
between poly Q peptides aggregation and Aβ-GFP aggregation.
First, DNAJB6 depends on its J-domain and subsequent
interaction with HSP70 to prevent the aggregation of Aβ-GFP
while the serine rich region but not J-domain was crucial for
DNAJB6 to prevent the aggregation of Poly Q stretches in HSP70
independent manner (Gillis et al., 2013). Second, HSPA1a that
does not reduce poly Q aggregation in HEK293 cells or DNAJB1
and DNAJA1 that only marginally lead to protection against poly
Q aggregation (Hageman et al., 2010), here they did reduce the
aggregation of Aβ42-GFP. Third, HSPB7, that was very potent in
reducing aggregation of poly Q proteins, and HSPB1 that did not
reduce poly Q aggregation (Vos et al., 2010), both exhibited the
opposite effect on Aβ-GFP aggregation.
Although Aβ42-GFP has been repeatedly used as a model to
study Aβ peptides aggregation and to discover new inhibitors
for Aβ aggregation (Caine et al., 2007; Park et al., 2009;
Chakrabortee et al., 2012), our data suggest that Aβ42-GFP
aggregation does not seem to reflect Aβ42 peptides aggregation.
This is based on our observations that: (1) Aβ42-GFP does not
form SDS-insoluble aggregates; (2) Aβ42-GFP aggregation is not
seeded by exogenous Aβ42 peptides; (3) although DNAJB6 was
effective in preventing the aggregation of Aβ42-GFP model, it
was dependent on functional interaction with HSP70, unlike its
mode of action as ‘‘peptide chaperone’’; (4), other members of
DNAJ family, HSPA1a and HSPB1 that were only marginally
effective as peptide chaperones were equally effective as DNAJB6
in preventing Aβ42-GFP aggregation. This behavior of Aβ-GFP
may be attributed to the existence of a GFP tag (MWt = 27 kDa)
that is several times bigger than the bound Aβ peptide (M Wt
= 4 kDa). Hence, GFP tag affects the biochemical and physical
characters of a small peptide/protein that mainly aggregates and
depends on complex conformational aspects.
Consistent with the previous findings that demonstrated that
cytosolic Aβ is mainly degraded by the proteasome (LaFerla
et al., 2007; Hong et al., 2014), we found that Aβ-GFP was much
accumulated in the cells when we inhibited the proteasome by
MG132 (data not shown). Mainly because Aβ42 is a short lived
substrate starting with a destabilized N-terminal (Asp) residue
that targets it to the N-end rule pathway followed by proteasomal
degradation (Brower et al., 2013). Therefore, alterations of the
ubiquitin-proteasome system may adversely affect the extent of
Aβ degradation. Nevertheless, a dysfunction in the endosomal-
lysosomal proteolysis or any of the autophagy related genes
was found to affect the neuronal functions and promotes the
accumulation of Aβ and tau toxic proteins (Ihara et al., 2012).
Our notion that DNAJB6 cannot prevent the extracellular
Aβ peptides from aggregation is compatible with our recent in
vitro data which showed that DNAJB6 was not able to prevent
the aggregation of Aβ peptides after a critical concentration of
Aβ fibrils are already formed (6% or more of Aβ monomers
are converted to fibrils) before introducing DNAJB6 chaperone
into the reaction mixture (Månsson et al., 2014a). It is worthy to
mention that we used Aβ oligomers in our initial experiments
as extracellular source of Aβ peptides with intracellular over-
expression of DNAJB6, however we did not find any prominent
difference between the behavior of Aβ oligomers compared with
Aβ fibrils. In addition, DNAJB6 was still unable to prevent
the further aggregation of Aβ oligomers and no co-localization
between Aβ oligomers and intracellular Aβ-GFP was detected.
Perhaps, over expression of C99 fragments of APP seems to be
a good alternative to generate intracellular Aβ accumulation and
study the impact of HSPs.
Conclusion
Hence, we conclude that DNAJB6 is an effective chaperone in
preventing the aggregation mediated by intracellularly generated
Aβ-GFP fusion but not the aggregation mediated by extracellular
Aβ peptides. Moreover, Aβ-GFP may not fully represent the
characteristics of Aβ peptides aggregation. Whereas this does
not preclude DNAJB6 as a potential modifier of and target in
AD, other models for intracellular Aβ aggregation are needed to
further test this.
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